单克隆抗体
免疫学
抗体
病毒学
抗原
传染病(医学专业)
大流行
免疫系统
肺结核
医学
生物
疾病
2019年冠状病毒病(COVID-19)
病理
作者
Patricia S. Grace,Bronwyn M. Gunn,Lenette L. Lu
标识
DOI:10.1016/j.copbio.2022.102818
摘要
The COVID-19 pandemic demonstrated that monoclonal antibodies can be deployed faster than antimicrobials and vaccines. However, the majority of mAbs treat cancer and autoimmune diseases, whereas a minority treat infection. This is in part because targeting a single antigen by the antibody Fab domain is insufficient to stop the dynamic microbial life cycle. Thus, finding the 'right' antigens remains the focus of intense investigations. Equally important is the antibody-Fc domain that has the capacity to induce immune responses that enhance neutralization, and limit pathology and transmission. While Fc-effector functions have been less deeply studied, conceptual and technical advances reveal previously underappreciated antibody potential to combat diseases from microbes difficult to address with current diagnostics, therapeutics, and vaccines, including S. aureus, P. aeruginosa, P. falciparum, and M. tuberculosis. What is learned about engineering antibodies for these challenging organisms will enhance our approach to new and emerging infectious diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI